Acurx Pharmaceuticals, Inc.
corporate_fare Company Profile
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ACXP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ACXP spans 10-Q, 424B3, S-1, 8-K.
Recent high-impact activity:
- Acurx Q3 Loss Widens to $2.58M as Going-Concern Doubt Persists on $9.7M Cash
- Acurx Enrolls First Patient in PATHFINDER Trial for Recurrent C. difficile
- FDA Conditionally Accepts Acurx's CIFBEZY Brand Name for Ibezapolstat
- Acurx Q2 Loss Narrows to $2.25M; FDA Path for Ibezapolstat Advances
- Acurx Q2 Loss Steady at $2.3M; Cash $10.7M, Going Concern Warning Reiterated
Financial Snapshot
Short Interest & Short Volume
1.63 days to coverFINRA reported short interest of 97,568 shares in ACXP as of the October 30, 2026 settlement, a 7.5% increase from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 40.0% of ACXP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ACXP, detected from its recent SEC filings · based on capital-structure filings through 2026-09-08.
Additional 1.5M Shares Registered for Resale · Remaining Proceeds Up to $2.8M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →